For patients with EGFR or ALK mutations, we adopted the MMSE assessment scale, EORTC QLQ-C30 scale, and DT scale to evaluate the relationship between changes in cognitive function during targeted treatment and QoL and psychological distress and cognitive function’s impact on treatment outcomes. This evidence concerns the gene EGFR and Abnormal emotional state.